ArticleThe Journal of clinical investigation2015
Can Parkinson's disease be cured by stimulating neurogenesis?
Article in The Journal of clinical investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Platelet-derived growth factor (PDGF)-BB protects dopaminergic neurons via activation of Akt/ERK/CREB pathways to upregulate tyrosine hydroxylase.CNS neuroscience & therapeutics · 2021Article
- PINK1 deficiency impairs adult neurogenesis of dopaminergic neurons.Scientific reports · 2021Article
- Microglia and Parkinson's disease: footprints to pathology.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Progranulin Protects Hippocampal Neurogenesis via Suppression of Neuroinflammatory Responses Under Acute Immune Stress.Molecular neurobiology · 2017Article
- Therapeutic approaches in Parkinson's disease and related disorders.Journal of neurochemistry · 2016Review
- Adult Neurogenesis and Gliogenesis: Possible Mechanisms for Neurorestoration.Experimental neurobiology · 2016Review
- Current disease modifying approaches to treat Parkinson's disease.Cellular and molecular life sciences : CMLS · 2016Review
- Exosomes as Novel Regulators of Adult Neurogenic Niches.Frontiers in cellular neuroscience · 2015Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
There have been many attempts at slowing down or even reversing the neurodegenerative process of Parkinson's disease (PD). To date, there are no treatments of proven value in this regard. One underexplored route to slow the neurodegenerative process is the use of agents that may stimulate neurogenesis in the subventricular zone. In animal models of PD, PDGF-BB has been shown to restore/protect against dopaminergic deficits caused by neurotoxins via increased neurogenesis in the subventricular zone. Previous work suggests that these new cells are not themselves dopaminergic but have trophic effects on residual dopaminergic cells in the substantia nigra. In this issue of the JCI, Paul et al. evaluate this agent in individuals with PD and show that i.c.v. administration of PDGF-BB is safe and well tolerated. This study lays the foundation for formal dose-finding studies and clinical trials to assess the efficacy of this agent as a potential neuroprotective treatment for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.